General Nieuws Regulated Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN mei 25, 2023
General Nieuws Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC EN mei 22, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL mei 19, 2023
General Nieuws Regulated Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023 EN mei 15, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL mei 12, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC EN NL mei 12, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL mei 5, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL mei 3, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL april 28, 2023
General Nieuws Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC EN april 27, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC EN NL april 24, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL april 14, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL april 7, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL maart 31, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL maart 24, 2023
General Nieuws Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL EN maart 20, 2023
General Nieuws Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes EN maart 14, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Negma Group EN NL maart 9, 2023
